Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-04-30FDA Approved: STEQEYMA — Original Application (CELLTRION USA, Inc.)
The FDA approved STEQEYMA (ustekinumab-stba) from Celltrion USA, Inc. under an Original Biologics License Application.
-
FDA approval · 2025-04-30FDA Approved: YESINTEK — Original Application (Biocon Biologics Inc.)
The FDA approved Yesintek (ustekinumab) from Biocon Biologics Inc. under an original Biologics License Application. It is indicated for plaq…
-
FDA approval · 2025-04-30FDA Approved: OTULFI — Original Application (Fresenius Kabi USA, LLC)
OTULFI (USTEKINUMAB-AAUZ) received FDA approval under an Original Application from Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS trial_result · 2025-04-30Clinical Trial Update: A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis [Phase 3]
A Phase III trial of SYHX1901 tablets for moderate to severe plaque psoriasis has not yet begun recruiting.
-
CLINICAL_TRIALS research · 2025-04-29Clinical Trial Update: A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy [Phase 3]
A Phase 3 clinical trial evaluating piclidenoson for moderate-to-severe plaque psoriasis focusing on safety and efficacy; the study is not y…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-04-28FDA Approved: STEQEYMA — Supplemental Application (CELLTRION USA, Inc.)
The FDA approved a supplemental application for STEQEYMA (ustekinumab-stba) from Celltrion USA, Inc.
-
CLINICAL_TRIALS trial_result · 2025-04-23Clinical Trial Update: Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients [Phase 3]
A Phase 3 trial comparing BAT2306 with Cosentyx for plaque psoriasis has completed, with the update focusing on efficacy and safety outcomes…
-
FDA approval · 2025-04-14FDA Approved: OTULFI — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental Biologics License Application for OTULFI (ustekinumab-AAUZ) from Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS research · 2025-04-13Clinical Trial Update: A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis [Phase 2]
A Phase 2 clinical trial update for HS-10374 evaluating efficacy and safety in mild-to-moderate plaque psoriasis, currently not yet recruiti…
-
CLINICAL_TRIALS research · 2025-04-11Clinical Trial Update: A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
A real-world study (RePhlect) is evaluating the effectiveness of Deucravacitinib in adults with plaque psoriasis in France, and the study is…
-
CLINICAL_TRIALS research · 2025-04-11Clinical Trial Update: A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis [Phase 2]
A Phase 2 clinical trial is underway to evaluate WD-890 for moderate-to-severe plaque psoriasis, and the study is currently recruiting.
-
CLINICAL_TRIALS research · 2025-04-09Clinical Trial Update: To Evaluate the Efficacy and Safety of RSS0393 Ointment in Patients With Plaque Psoriasis Phase II Study [Phase 2]
A Phase II clinical trial to assess the efficacy and safety of RSS0393 Ointment in plaque psoriasis, sponsored by Jiangsu HengRui Medicine C…
-
FDA approval · 2025-04-07FDA Approved: ADALIMUMAB — Supplemental Application (CELLTRION USA, Inc.)
FDA approved a supplemental application for ADALIMUMAB-AATY, a biosimilar adalimumab from Celltrion USA, Inc., in connection with its regula…
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis [Phase 2]
Phase 2 study evaluating DC-806 in moderate-to-severe plaque psoriasis has completed, and results were posted on 2025-04-04.
-
FDA approval · 2025-04-01FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab (Stelara) by Janssen Biotech, Inc.
-
CLINICAL_TRIALS research · 2025-04-01Clinical Trial Update: Evaluation of the Efficacy and Tolerance of the Medical Device RL3020-DP0364 in Adult Population With Stable Mild Plaque Psoriasis, Dry Skin and Pruritus [NA]
An ongoing clinical trial evaluating the safety and efficacy of the medical device RL3020-DP0364 in adults with stable mild plaque psoriasis…
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants [Phase 3]
A Phase 3 pediatric study evaluating the efficacy, safety, and pharmacokinetics of subcutaneously administered guselkumab for chronic plaque…
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis [Phase 2]
This Phase 2 trial update assesses the pharmacokinetics, safety, and efficacy of two doses of bimekizumab in adolescents with moderate to se…
-
CLINICAL_TRIALS trial_result · 2025-03-21Clinical Trial Update: A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis [Phase 3]
A Phase 3 trial in adult Chinese subjects with stable plaque psoriasis compared LEO 90100 to Daivobet ointment to evaluate efficacy and safe…
-
FDA approval · 2025-03-13FDA Approved: USTEKINUMAB-TTWE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application for USTEKINUMAB-TTWE from Quallent Pharmaceuticals Health LLC, updating the product’s labeling a…
-
CLINICAL_TRIALS trial_result · 2025-03-11Clinical Trial Update: A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis [Phase 2]
Clinical trial update reporting the results of a Phase 2 study evaluating safety, tolerability, and efficacy in subjects with plaque psorias…
-
CLINICAL_TRIALS trial_result · 2025-03-11Clinical Trial Update: A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis [Phase 3]
A Phase 3 study evaluating a recombinant anti-IL-17A humanized monoclonal antibody in Chinese patients with moderate-to-severe plaque psoria…
-
FDA approval · 2025-03-10FDA Approved: TAZAROTENE — Supplemental Application (Mayne Pharma)
The FDA approved a supplemental application for tazarotene submitted by Mayne Pharma, extending its approved use.
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis [Phase 1]
A Phase 1 study evaluating AK111 for moderate-to-severe plaque psoriasis has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-03Clinical Trial Update: A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis [Phase 1, Phase 2]
The AK101 study in moderate to severe plaque psoriasis has completed Phase 1 and Phase 2.